PNC Financial Services Group
LXEO icon

PNC Financial Services Group’s Lexeo Therapeutics LXEO Stock Holding History

PNC Financial Services Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.9K Buy
505
+18
+4% +$128 ﹤0.01% 4469
2025
Q4 		$4.84K Sell
487
-186
-28% -$1.7K ﹤0.01% 4245
2025
Q3 		$4.47K Buy
+673
New +$3.25K ﹤0.01% 4246

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PNC Financial Services Group's LXEO Position: Q1 2026 in Review

PNC Financial Services Group increased its Lexeo Therapeutics (LXEO) stake by 3.7% in Q1 2026, buying an estimated $128 and bringing the position to 505 shares worth $2.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4469.

PNC Financial Services Group first reported a position in LXEO in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.84K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • PNC Financial Services Group held 505 shares of Lexeo Therapeutics worth $2.9K as of Q1 2026.
  • PNC Financial Services Group bought 18 Lexeo Therapeutics shares in Q1 2026, an estimated $128.
  • Lexeo Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4469 holding.
  • PNC Financial Services Group first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • PNC Financial Services Group's Lexeo Therapeutics position peaked at $4.84K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.